yl)-2,2-dimethylpropanamide (2) as outlined in Chart 1. Compound 2 was synthesized from 1-acetyl-4,6-dimethylindoline according to the method previously reported 11) and then nitrated to give compound 3 with a nitro group at the 5-position. To prepare 1a-f, h-k, compound 3 was hydrolyzed to give compound 4 with no substituents at the 1-position, and then various chains, e.g. straight alkyl, branched alkyl, and ether chains, were introduced to 4 at the 1-position using i-Pr 2 NEt or NaH as a base to give 5a-f, h, i. Separately, compound 4 was alkylated with 2-bromoethanol at the 1-position, followed by mesylation, and then the mesylate compound was converted to thioether derivatives 5j, k. The nitro moiety of compounds 5a-f, h-k was hydrogenated, followed by the reaction with Boc-NHSO 2 Cl, which was previously generated by the reaction of chlorosulfonyl isocyanate with tert-BuOH, to give 6a-f, h-k with Boc-protected sulfamoylamino moiety at the 5-position. To prepare compound 6g with a cyclopentyl moiety at the 1-position, the nitro moiety of 3 was converted to Bocprotected amino moiety. The acetyl moiety was hydrolyzed, and then a cyclopentyl moiety was introduced to give compound 7. The Boc group of 7 was cleaved by treating with HCl, followed by conversion to 6g according to the method described above. Finally, the Boc group of 6a-k was deprotected with HCl to obtain compounds 1a-k as a hydrochloride salt.
Indoline-based sulfamide derivatives with a methyl or butyl moiety at the 2-position (9a-d) were prepared as outlined in Chart 2. 3,5-Dimethylphenylhydrazine (10) was converted to 2,4,6-trimethylindole (11) by Fisher indole synthesis. Compound 11 was reduced by NaBH 3 CN and acetylated at the 1-position to give compound 12. Separately, the ester function of ethyl 4,6-dimethylindole-2-carboxylate (13) 12) was reduced with LiAlH 4 , followed by successive oxidation with activated MnO 2 to afford an aldehyde derivative 14. Then, compound 14 was converted to 15 with a butyl moiety at the 2-position by the Wittig reaction and successive hydrogenation, followed by reduction of the indole ring. Compounds 12 and 15 were converted to 1,2-disubstituted indolines 9a-d via deacetylated compounds 16 and 17 according to the method described in Chart 1.
Indoline-based sulfamide derivatives with ether or thioether moiety at the 2-position (18a-d) were synthesized as outlined in Chart 3. An ester compound 13 was reduced with LiAlH 4 and NaBH 3 CN, and then acetylated to give compound 19. Compound 19 was selectively deacetylated at the 2-position, and then alkylated with MeI and EtI to give 20 and 21, respectively. Compounds 20 and 21 were converted to 18a, b via 5-nitroindoline derivatives 22a, b as described in Chart 1. Separately, compound 19 was converted to 23 with a hydroxymethyl moiety at the 2-position as described in Chart 1, and then the hydroxymethyl moiety was converted to the thioether moiety to give 22c, d, followed by conversion to compounds 18c, d.
An indoline-based sulfamide derivative with a methoxyethyl moiety at the 3-position (24) was synthesized as outlined in Chart 4. 4,6-Dimethylindole (25) was reacted with oxalyl chloride, and successively esterified to give a product with ethyl oxalate at the 3-position, which was reduced with LiAlH 4 and NaBH 3 CN, and protected with Boc group to obtain a compound with a hydroxyethyl moiety at the 3-position. Then, the compound was methylated at the hydroxyl group, followed by exchanging Boc for an acetyl Reagents, conditions and yields: (i) acetone, PPA, 140°C, 80%; (ii) (a) NaBH 3 Chart 3. Synthesis of Indoline-Based Sulfamide Derivatives with Ether or Thioether Moiety at the 2-Position group to give a 3-methoxyethyl indoline derivative 26, which was then converted to 24 in a similar manner to that described in Chart 1. Compound 27 (Pactimibe) with a carboxymethyl moiety, and compounds 28 (KY-455) and 29 with no substituents at the 5-position were synthesized according to the methods previously reported. 7, 11) 
Results and Discussion
We have reported the synthesis and biological activities of Pactimibe, an indoline-based ACAT inhibitor with a carboxymethyl group at the 5-position. 7) Pactimibe exerted inhibitory effects on macrophage ACAT activities and was efficiently absorbed orally, suggesting that it would have potent anti-atherosclerotic effects; however, clinical studies failed to show a plaque-reducing effect in CAD patients.
10) It remains to be determined whether Pactimibe is unable to retard atherosclerosis due to insufficient ACAT inhibition and/or whether ACAT inhibition itself is ineffective at reducing human atherosclerotic plaques. Pactimibe showed high water solubility and bioavailability whilst maintaining high ACAT inhibitory activity, while its PBR was high because it is a relatively large lipophilic molecule with an ionizable moiety. The high PBR may have resulted in low partition into atherosclerotic plaques in some patients. Thus, we attempted to introduce a sulfamoylamino group instead of the carboxyl moiety at the 5-position, which is unionized around neutral pH, to find a new bioavailable inhibitor with low lipophilicity and PBR. Lipophilicity (log D 7.0 ), rabbit PBR and inhibitory activity against foam cell formation of the sulfamide derivatives and related compounds were determined (Table 1) . Compound 1d with a sulfamoylamino group at the 5-position and an octyl chain at the 1-position showed lower log D 7.0 (4.63) than 29 (5.10), which had no substituent at the 5-position, 11) and higher log D 7.0 than Pactimibe (2.85), which had a carboxymethyl moiety, while compound 1d showed lower PBR than 29 and Pactimibe (93.2, 99.2, 98.1%, respectively). On the other hand, the AFCF activity of 1d (IC 50 : 0.02 mM) was about 6-fold and 150-fold higher than those of 29 (IC 50 : 0.11 mM) and Pactimibe (IC 50 : 3.0 mM), respectively, indicating that introduction of a sulfamoylamino group is useful for increasing activity. To find a new well-balanced compound for lipophilicity, PBR and AFCF activity, various alkyl chains were introduced at the 1-, 2-and 3-positions of the indoline ring. Shortening the alkyl chain at the 1-position from octyl (1d) to pentyl (1c), butyl (1b) and propyl (1a) decreased log D 7.0 , PBR, and AFCF activity. Compound 1a showed much lower log D 7.0 and PBR (2.03, 72.5%, respectively) than Pactimibe, while it still had about 3-fold more potent AFCF activity (IC 50 : 0.95 mM) than Pactimibe. Compound 1c with a pentyl chain showed much lower log D 7.0 (2.87) and PBR (80.1%), and 30-fold stronger activity (IC 50 : 0.094 mM) than the corresponding compound 28 (KY-455) with no substituents at the 5-position. 11, 13) All sulfamide derivatives prepared, except for 24, showed lower PBR and stronger AFCF activities than Pactimibe. Interestingly, 1b and 9a, and 1c and 9d showed similar AFCF activities, respectively, suggesting that a relatively small lipophilic chain at the 1-or 2-position is enough to interact with ACAT protein in sulfamide derivatives. Overall, AFCF activity and PBR increased in dependence on lipophilicity (log D 7.0 ) in the sulfamide derivatives synthesized: there were significant co-relationships between log(AFCF IC 50 ) and log D 7.0 (r 2 ϭ0.777), between PBR and log D 7.0 (r 2 ϭ0.763), and between log(AFCF IC 50 ) and PBR (r 2 ϭ0.831), respectively. Sulfamide derivatives were demonstrated to maintain potent AFCF activities at much lower log D 7.0 and PBR than Pactimibe and KY-455 derivatives (28, 29). Low lipophilic sulfamide derivatives may have interacted with an ACAT protein in a manner different from those of high lipophilic inhibitors. Furthermore, in macrophages, the sulfamide derivatives may have efficiently reached the enzyme without being trapped by culture medium proteins, cell membrane, intracellular lipid and/or proteins. In particular, compounds 1h, 1i and 9b with an alkoxy chain showed log D 7.0 lower than 2.0 and PBR around 60%. Among these, 1i with the most potent AFCF activity was selected for further evaluation.
Compound 1i potently inhibited hepatic ACAT activity (IC 50 : 0.21 mM), suggesting that it would exert hypolipidemic effects by inhibiting hepatic very low density lipoprotein (VLDL) secretion. Compound 1i showed good oral absorption in rats, rabbits, and dogs ( Table 2 ). The maximal plasma concentration of 1i was higher than its IC 50 values for AFCF and hepatic ACAT inhibitory activities. Unlike Pactimibe, compound 1i showed very low PBR; thus, the plasma concentration of the unbound form available for partition to the target organ was considered to be much higher than that of Pactimibe. Indeed, the partition ratio of Pactimibe from plasma to the atherosclerotic aorta was significantly lower than that of 1i: 0.10Ϯ0.03 vs. 0.85Ϯ0.10 (nϭ3, pϽ0.01, Student's t-test). Furthermore, the anti-foam cell formation activity of 1i at 10 mM was not affected by 5% albumin (% inhibition; 65.7Ϯ9.9 vs. 60.5Ϯ5.4, nϭ3), while that of Pactimibe was markedly reduced (% inhibition; 74.5Ϯ11.5 vs. 33.1Ϯ6.2, nϭ3). Compound 1i at 10 mM markedly inhibited the cholesterol esterification in isolated atherosclerotic aortas of Kurosawa and Kusanagi hypercholesterolemic (KHC) rabbits incubated with serum (% inhibition; 70.8Ϯ3.6), while Pactimibe had little effect, probably due to its high PBR.
In conclusion, an indoline structure with a sulfamoylamino moiety is a useful scaffold to design a potent ACAT inhibitor with low lipophilicity and PBR. Compound 1i showed lower lipophilicity and PBR, and maintained higher inhibitory activity against cholesterol esterification in macrophages and atherosclerotic aorta than Pactimibe, even in the presence of albumin or serum, probably due to its lower PBR. In addition, it also inhibited hepatic ACAT activity. Compound 1i would more potently and consistently prevent atherosclerotic plaque formation and promote its regression than Pactimibe.
Experimental
General Procedures Chemicals were obtained from commercial sources and used without purification. Reactions were monitored by TLC on Merck precoated silica gel 60 F 254 (0.25 mm) plates. Column chromatography was performed on silica gel (Daisogel No. 1001W; Daiso, Osaka, Japan). Melting points were measured on a melting point apparatus (MP-500P; Yanaco, Kyoto, Japan) and are uncorrected. IR spectra were obtained with an infrared spectrometer (FT-IR 8200PC; Shimadzu, Kyoto, Japan).
1 H-NMR spectra were recorded on a nuclear magnetic resonance spectrometer at 400 MHz (JNM-AL400; JEOL, Tokyo, Japan) or 90 MHz (R-1900; Hitachi, Tokyo) using tetramethylsilane as an internal standard. MS spectra were obtained on a QTRAP LC/MS/MS system (API2000, Applied Biosystems; Foster, CA, U.S.A.).
Procedure for the Synthesis of 1i Compound 1i was synthesized from 2 via 3, 4, 5i, and 6i as follows:
To a solution of 2 (1.99 g, 6.90 mmol) in AcOH (20 ml) in an ice bath was added fuming HNO 3 (0.41 ml, 10 mmol). The reaction mixture was stirred at room temperature overnight and at 50°C for 4 h. After the mixture was poured into water, the precipitate formed was collected by filtration. A solution of the collected material in CHCl 3 (300 ml) was washed with saturated NaHCO 3 solution and brine, dried over Na 2 SO 4 , and then evaporated under reduced pressure. The residue was purified by column chromatography (AcOEt : n-hexaneϭ1 : 1) to give 3 as a crystalline solid (2.2 g, 96% yield). 1 
N-(4,6-Dimethyl-5-nitroindolin-7-yl)-2,2-dimethylpropanamide (4):
To a solution of 3 (800 mg, 2.4 mmol) in MeOH (8 ml) was added NaOH aqueous solution (480 mg, 12.0 mmol/3 ml), and the mixture was stirred at 80°C for 15 min. After evaporation under reduced pressure, the residue was dissolved in CHCl 3 (50 ml), and the solution was washed with water and brine, dried over Na 2 SO 4 , and then evaporated under reduced pressure. The residue was purified by column chromatography (CHCl 3 : MeOHϭ50 : 1) to give 4 as a crystalline solid (680 mg, 97% yield).
1 H-NMR (CDCl 3 ) d: 1.23 (9H, s), 2.14 (3H, s), 2.16 (3H, s), 3.01 (2H, t, Jϭ8.5 Hz), 3.67 (2H, t, Jϭ8.5 Hz), 4.26 (1H, s), 7.03 (1H, s).
To a solution of 4 (50 g, 0.17 mol) in N,N-dimethylformamide (DMF) (500 ml) were added i-Pr 2 NEt (58.5 ml, 0.34 mol) and 2-bromoethyl ethyl ether (58 ml, 0.51 mol), and the mixture was stirred at 110°C for 18 h under an N 2 atmosphere. After cooling, the reaction mixture was diluted with AcOEt (2 l), and washed with water, 5% citric acid solution, and brine. The organic layer was dried over Na 2 SO 4 , and evaporated under reduced pressure to give a crystalline product. The products were recrystallized from MeOH (60 ml) to give 5i (45.0 g, 72% yield 
A suspension of 5i (45.0 g, 0.12 mol) in MeOH (700 ml) was hydrogenated at 0.3 MPa in the presence of 10% Pd-C (9.0 g) at 40°C for 20 h. After removal of the catalyst by filtration, the filtrate was evaporated under reduced pressure. The residue was rinsed with i-Pr 2 O (150 ml), and then the precipitate was collected by filtration. (30) was obtained as a crystalline solid (35.0 g). To a stirred solution of tert-BuOH (15.0 ml, 0.157 mol) in CH 2 Cl 2 (350 ml) was added chlorosulfonyl isocyanate (13.7 ml, 0.157 mol) at Ϫ10°C, and then the mixture was stirred at the same temperature for 30 min. To the solution were added 30 (35.0 g, 0.105 mol) and Et 3 N (22.0 ml, 0.158 mol), and the mixture was stirred for 1 h at the same temperature. After addition of CH 2 Cl 2 , the solution was washed with 5% citric acid solution, saturated NaHCO 3 solution, water, and brine. The organic layer was dried over Na 2 SO 4 , and evaporated under reduced pressure. The residue was purified by column chromatography (AcOEt : CHCl 3 ϭ1 : 1) to give 6i as a crystalline solid (47.5 g, 75% yield). 
To a solution of 6i (47.5 g, 0.93 mol) in HCO 2 H (190 ml) in an ice bath was added 8.7 M HCl in i-PrOH (32 ml, 0.28 mol), and the mixture was stirred at the same temperature for 30 min. After the solution had been poured into Et 2 O (5.9 l) with stirring, the precipitate formed was collected by filtration. To a suspension of the precipitate in MeOH (180 ml) was added Et 2 O (3.9 l) with stirring, and the precipitate was collected by filtration to obtain compound 1i as a crystalline solid (33.5 g, 80% yield Procedure for the Synthesis of 1a Compound 1a was synthesized from 4 via 5a according to the procedure for 1i. The reaction condition of the preparation for 5a was changed as follows:
To a stirred solution of 4 (500 mg, 1.72 mmol) in DMF (5 ml) in an ice bath was added a 60% suspension of NaH in mineral oil (103 mg, 2.6 mmol) portionwise under an N 2 atmosphere. After stirring at the same temperature for 15 min, propyl iodide (0.34 ml, 3.5 mmol) was added to the mixture in an ice bath, and was further stirred for 18 h at room temperature. After addition of water (50 ml), the reaction mixture was extracted with AcOEt. The organic layer was washed with water and brine, dried over Na 2 SO 4, and evaporated under reduced pressure. The residue was purified by column chromatography (CHCl 3 : MeOHϭ50 : 1) to give 5a as a crystalline solid (0.42 g, 80% yield). 1 Procedure for the Synthesis of 1g Compound 1g was synthesized from 3 via 7 and 6g. Compound 6g was converted to 1g according to the procedure for 1i. Compound 6g was prepared via 31, 33, and 7 as follows: 95 mmol) in EtOH (24 ml) was added 5.0 M NaOH aqueous solution (6 ml, 30 mmol), and the mixture was refluxed for 1 h. After addition of water (75 ml), the reaction mixture was stirred for 15 min at room temperature. The precipitate formed was collected by filtration to obtain 33 as a crystalline solid (1.47 g, 68% yield). 1 (1H, s) . (7): To a solution of 33 (3.14 g, 8.69 mmol) in DMF (30 ml) were added i-Pr 2 NEt (3.0 ml, 17 mmol), bromocyclopentane (1.86 ml, 17.4 mmol), KI (721 mg, 4.34 mmol), and hydroquinone (48 mg, 0.44 mmol), and the mixture was stirred for 15 h at 90°C. After the mixture was poured into water (100 ml), the precipitate formed was collected by filtration. A solution of the obtained powder in CHCl 3 (100 ml) was washed with water and brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. The residue was purified by column chromatography (AcOEt : CHCl 3 ϭ1 : 5) to give a crystalline powder. The powder was rinsed with i-Pr 2 O to give 7 as a crystalline solid (0.78 g, 21% yield (1H, s) .
To a solution of 7 (0.76 g, 1.8 mmol) in HCO 2 H (7.6 ml) in an ice bath was added 8.7 M HCl in i-PrOH (0.61 ml, 5.3 mmol), and the mixture was stirred at the same temperature for 15 min. After addition of a mixed solvent of i-Pr 2 O-n-hexane, the supernatant was removed by decantation to give an oily product. A solution of the oil in AcOEt (100 ml) was washed with saturated NaHCO 3 solution and brine, dried over Na 2 SO 4, and evaporated under reduced pressure. The residue was treated with chlorosulfonyl isocyanate according to the method of preparation for 6i to give 6g as a crystalline solid (618 mg, 69% yield). 24 (1H, s), 10.82 (1H, s) . Procedure for the Synthesis of 1j Compound 1j was synthesized from 4 via 5j. Compound 5j was converted to 1j according to the procedure for 1i. Compound 5j was prepared as follows:
To a solution of 4 (8.0 g, 28 mmol) in DMF (40 ml) were added i-Pr 2 NEt (14 ml, 82 mmol) and 2-bromoethanol (5.8 ml, 82 mmol), and the mixture was stirred for 6.5 h at 120°C under an N 2 atmosphere. After addition of 5% citric acid solution (200 ml), the mixture was extracted with AcOEt. The organic layer was washed with 5% NaHCO 3 solution and brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. The crystalline residue was rinsed with CHCl 3 (50 ml) to obtain 34 (4.88 g, 53% yield). The filtrate was evaporated under reduced pressure and purified by column chromatography (AcOEt : CHCl 3 ϭ1 : 3). The crystalline residue was rinsed with AcOEt to obtain 34 (1.33 g, 14% yield). 
N-[1-(2-Mercaptoethyl)-4,6-dimethyl-5-nitroindolin-7-yl]-2,2-dimethylpropanamide (35):
To a solution of 34 (6.21 g, 18.5 mmol) in CHCl 3 (62 ml) in an ice bath were added MsCl (2.8 ml, 36 mmol) and Et 3 N (5.1 ml, 36 mmol), and the mixture was stirred for 30 min at the same temperature. After addition of AcOEt, the mixture was washed with 5% citric acid solution, saturated NaHCO 3 solution and brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. The crystalline residue was rinsed with Et 2 O to give a mesylate derivative. To a solution of the obtained solid (7.38 g, 17.8 mmol) in DMF (73 ml) was added potassium thioacetate (3.05 g, 26.7 mmol), and the mixture was stirred for 30 min at 70°C. After addition of water, the mixture was extracted with AcOEt. The extract was washed with water and brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. The crystalline residue was rinsed with Et 2 O to give a thioacetate derivative as a solid. To a solution of the solid (6.5 g, 17 mmol) in MeOH (130 ml) in an ice bath was added 2.0 M NaOH aqueous solution (9.9 ml, 20 mmol), and the mixture was stirred for 1 h at the same temperature. After addition of 5% citric acid solution, the mixture was evaporated under reduced pressure, and then the residue was extracted with AcOEt. The organic layer was washed with water and brine, dried over Na 2 SO 4 
N-[4,6-Dimethyl-1-(2-methylthioethyl)-5-nitroindolin-7-yl]-2,2-dimethylpropanamide (5j):
To a solution of 35 (1.5 g, 4.3 mmol) in DMF (15 ml) were added i-Pr 2 NEt (1.45 ml, 8.5 mmol) and methyl iodide (0.53 ml, 8.5 mmol), and the mixture was stirred for 0.5 h at room temperature. After dilution with AcOEt, the mixture was washed with 5% citric acid solution, water and brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. The crystalline residue was rinsed with i-Pr 2 O to obtain 5j (1.42 g, 91% yield). Procedure for the Synthesis of 9a Compound 9a was synthesized from 10 via 11 and 12. To compound 12 was introduced a pivaloylamino moiety at the 7-position according to the previous report 11) and then the product was converted to 9a according to the procedure for 1a. Compound 11 and 12 were prepared as follows:
2,4,6-Trimethylindole (11): To a mixture of 10 14) (533 mg, 3.91 mmol) and acetone (0.29 ml, 3.9 mmol) was added polyphosphoric acid (1.5 g), and the mixture was heated gradually until 140°C for 30 min. After addition of water (10 ml), the mixture was extracted with Et 2 O. The organic layer was washed with water, saturated NaHCO 3 solution, and brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. The residue was purified by column chromatography (AcOEt : n-hexaneϭ1 : 20) to give 11 as a crystalline solid (500 mg, 80% yield). 1 1-Acetyl-2,4,6-trimethylindoline (12): To a solution of 11 (480 mg, 3.01 mmol) in AcOH (2 ml) in an ice bath was added NaBH 3 CN (378 mg, 6.02 mmol), and then the mixture was stirred for 2 h. After the mixture was poured into cold water (8 ml), AcOEt (5 ml) was added, and then the mixture was neutralized with NaOH. The organic layer was separated, washed with water, dried over Na 2 SO 4 , and evaporated under reduced pressure. To a solution of the residue in benzene (2 ml) was added Ac 2 O (0.4 ml, 4 mmol), and then the mixture was stirred for 1 h. After removal of the solvent under reduced pressure, a solution of the residue in CHCl 3 (50 ml) was washed with water, saturated NaHCO 3 solution, and brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. The residue was purified by column chromatography (AcOEt : n-hexaneϭ1 : 1) to give 12 as a crystalline solid (520 mg, 85% yield (14): To a suspension of LiAlH 4 (4.11 g, 108 mmol) in Et 2 O (320 ml) in an ice bath was added 13 12) (15.7 g, 72.2 mmol) portionwise, and then the mixture was stirred at the same temperature for 1 h. After addition of water and AcOEt (300 ml), the mixture was filtrated. The two layers of the filtrate were separated, and the organic layer was dried over Na 2 SO 4 , and evaporated under reduced pressure. To a solution of the residue in CH 2 Cl 2 (540 ml) was added activated MnO 2 (43.9 g, 505 mmol). After stirring at room temperature for 15 h, activated MnO 2 (10.0 g, 115 mmol) was added, and stirred for 6 h. The mixture was filtrated, and the filtrate was evaporated under reduced pressure. The residue was purified by column chromatography (AcOEt : n-hexaneϭ1 : 1) to give 14 as a crystalline solid (7.78 g, 62% yield).
1 H-NMR (CDCl 3 ) d: 2.43 (3H, s), 2.54 (3H, s), 6 .81 (1H, s), 7.06 (1H, s), 7.25 (1H, s), 9.15 (1H, s), 9.78 (1H, s). 1-Acetyl-2-butyl-4,6-dimethylindoline (15): To a suspension of allyltriphenylphosphonium bromide (25.0 g, 65.3 mmol) in tetrahydrofuran (THF) (200 ml) was added 1.6 M n-BuLi in hexane (65 ml, 65 mmol) dropwise below 10°C. The reaction mixture was stirred at the same temperature for 20 min. To the mixture was added 14 (5.66 g, 32.7 mmol) in THF (50 ml) at the same temperature. After stirring for 20 min, water was added, and the mixture was extracted with AcOEt. The organic layer was washed with brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. A solution of the residue in MeOH (400 ml) was hydrogenated at 0.4 MPa in the presence of 10% Pd-C (2.70 g) at 35°C for 16 h. After removal of the catalyst by filtration, the filtrate was evaporated under reduced pressure. The residue was purified by column chromatography (AcOEt : n-hexaneϭ1 : 3). To a solution of the product in AcOH (38 ml) was added NaBH 3 CN (2.64 g, 37.8 mmol) portionwise at 10°C, and then the mixture was stirred for 30 min at the same temperature. After addition of NaOH aqueous solution (22 g/72 ml) at below 20°C, the mixture was extracted with AcOEt. The organic layer was washed with saturated NaHCO 3 solution and brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. To a solution of the residue in CHCl 3 (39 ml) were added Ac 2 O (2.7 ml, 29 mmol), and Et 3 N (4.0 ml, 29 mmol). After stirring at room temperature for 30 min, the reaction mixture was washed with 10% citric acid solution, saturated NaHCO 3 solution and brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. The residue was purified by column chromatography (AcOEt : nhexaneϭ1 : 2) to give 15 (3.48 g, 42% yield). 2-Acetoxymethyl-1-acetyl-4,6-dimethylindoline (19): To a suspension of LiAlH 4 (2.10 g, 55.3 mmol) in Et 2 O (160 ml) in an ice bath was added 13 (8.0 g, 37 mmol) portionwise, and then the mixture was stirred at the same temperature for 1 h. After addition of water and AcOEt (300 ml), the mixture was filtrated. The two layers of the filtrate were separated, and the organic layer was dried over Na 2 SO 4 , and evaporated under reduced pressure to give 2-hydroxymethyl-4,6-dimethylindole (36) as a crystalline solid. To a solution of 36 in AcOH (60 ml) was added NaBH 3 CN (5.14 g, 73.6 mmol) portionwise at 10°C, and then the mixture was stirred for 30 min at the same temperature. After addition of NaOH aqueous solution (40 g/140 ml) below 20°C, the mixture was extracted with AcOEt. The organic layer was washed with saturated NaHCO 3 solution and brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. To a solution of the residue in CHCl 3 (70 ml) were added Ac 2 O (10.4 ml, 110 mmol), and Et 3 N (15.4 ml, 110 mmol). After stirring at room temperature for 16 h, the reaction mixture was washed with 10% citric acid solution, saturated NaHCO 3 solution and brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. The crystalline residue was rinsed with i-Pr 2 O to obtain 19 (7.43 g, 77% yield). 1-Acetyl-2-hydroxymethyl-4,6-dimethylindoline (37): To a solution of 19 (17.4 g, 66.6 mmol) in MeOH (175 ml) in an ice bath was added 1.0 M LiOH aqueous solution (80 ml, 80 mmol), and then the mixture was stirred at the same temperature for 0.5 h. After addition of 5% citric acid solution (100 ml), the solvent was removed under reduced pressure. The precipitate formed was collected by filtration to obtain 37 as a crystalline solid (14.0 g, 96% yield). 37 g, 34 mmol) . After stirring for 10 min at the same temperature, MeI (11.8 ml, 190 mmol) was added, and stirred for 1.5 h at 80°C. After addition of 5% citric acid solution (500 ml), the mixture was extracted with AcOEt. The organic layer was washed with saturated NaHCO 3 solution and brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. The residue was purified by column chromatography (AcOEt : n-hexaneϭ2 : 1) to give 20 as a crystalline solid (3.95 g, 45% yield). 1 2-(4,6-Dimethylindol-3-yl)ethanol (38): To a solution of 4,6-dimethylindole (25) (26.0 g, 179 mmol) in Et 2 O (260 ml) in an ice bath was added oxalyl chloride (30.6 ml, 322 mmol). After stirring for 4 h at room temperature, the reaction mixture was evaporated under reduced pressure. A solution of the residue in EtOH (200 ml) was stirred for 1 h at room temperature, and then the solvent was evaporated under reduced pressure. After dilution with AcOEt, the solution was washed with water, brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. The residue was purified by column chromatography to give a crystalline residue. The residue was rinsed with Et 2 O to give ethyl (4,6-dimethylindol-3-yl)oxoacetate (39) as a crystalline solid (21.2 g, 54% yield). To a suspension of LiAlH 4 (9.36 g, 247 mmol) in THF (200 ml) was added the compound 39 (20.2 g, 82.4 mmol) at room temperature. The reaction mixture was refluxed for 1 h, and then water was added. After removal of insoluble material by filtration, the organic layer was separated, dried over Na 2 SO 4 , and evaporated under reduced pressure to give 38 as a crystalline solid (15.8 g, 100% yield 3 g, 107 mmol) , and the reaction mixture was stirred for 2 h at room temperature. After evaporation under reduced pressure, the residue was purified by column chromatography (AcOEt : n-hexaneϭ1 : 3) to give tert-butyl 3-(2-hydroxyethyl)-4,6-dimethylindoline-1-carboxylate (42) as an oil (22.1 g, 89% yield). To a solution of 42 (22.1 g, 75.8 mmol) in DMF (110 ml) in an ice bath were added methyl iodide (9.6 ml, 0.15 mol) and 60% suspension of NaH in mineral oil (3.98 g, 99.5 mmol), and the mixture was stirred for 1 h at the same temperature. After addition of 5% citric acid solution, the mixture was extracted with AcOEt. The organic layer was washed with water, saturated NaHCO 3 solution, brine, dried over Na 2 SO 4 , and evaporated under reduced pressure to give tert-butyl 3-(2-methoxyethyl)-4,6-dimethylindoline-1-carboxylate (43) as an oil (24.1 g). To a solution of 43 (24.0 g, 78.6 mmol) in HCO 2 H (72 ml) in an ice bath was added 8.7 M HCl in i-PrOH (29 ml, 0.25 mol). The mixture was stirred for 15 min at the same temperature. After addition of water, the mixture was extracted with AcOEt. The organic layer was washed with saturated NaHCO 3 solution, brine, dried over Na 2 SO 4 , and evaporated under reduced pressure to give 41 as an oil (15.6 g, 97% yield). After stirring for 1 h at room temperature, the mixture was washed with 5% citric acid solution, saturated NaHCO 3 solution, brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. The residue was purified by column chromatography (AcOEt : n-hexaneϭ1 : 2) to give 26 as a crystalline solid (19.7 g, 100% yield). 1 15) Acetanilide, benzonitrile, benzene, bromobenzene, biphenyl and hexachlorobenzene, the log D 7.0 values of which are known, were used as reference substances. Test compounds and reference substances were dissolved in acetonitrile containing 1% dimethylsulfoxide (DMSO) at 10 mg/ml, and then 10 ml of the solution was injected into the HPLC system. The HPLC equipment consisted of a pump (PU-980; JASCO, Tokyo, Japan), a UV detector (UV-970; JASCO), an autoinjector (AS-950; JASCO), and a Cosmosil 5C18-AR-II column (5 mm, 4.6 mmϫ150 mm; Nacalai Tesque, Kyoto, Japan). Phosphate buffer (pH 7.0)-MeOH (8 : 2) was used as the eluent. The capacity factors of test substances and reference substances were calculated from their retention time. The log D 7.0 values of test compounds were calculated using these capacity factors and the reported log D 7.0 values of reference substances.
Biological Evaluations of Compounds All experiments were conducted according to the guidelines for animal experiments of our institute and the Guidelines for Animal Experimentation approved by the Japanese Association of Laboratory Animal Science and the Japanese Pharmacological Society.
Plasma Protein Binding ratio (PBR): The plasma protein binding ratio was estimated by an ultracentrifugation method. 16) Test compounds were dissolved in rabbit plasma (10 mg/ml), which was isolated from blood taken from male Japanese white rabbits (JW rabbits, 6 months old; Japan SLC Inc., Hamamatsu, Japan). The concentration of the plasma was determined using the API 2000 QTRAP LC-MS/MS system (Applied Biosystems). The plasma was then separated into three layers by ultracentrifugation at 436000ϫg for 150 min with a small ultracentrifuge (CS100GX; Hitachi Koki, Hitachinaka, Japan). The concentrations of the test compounds in the middle layer (protein-free fraction) were determined using the API 2000 QTRAP LC-MS/MS system. From the total and protein-free fraction concentrations, the protein binding ratio of the test compounds was calculated.
Plasma and Arterial Levels of Compounds after Oral Administration: Compound 1i and Pactimibe sulfate were suspended in 5% arabic gum and administered orally at 10 mg/kg to male Sprague-Dawley (SD) rats (7 weeks old; Japan SLC Inc.), beagles (47, 60 months; NARC Co., Yamatake, Japan), and male JW rabbits (5-7 months; Japan SLC Inc.). Blood samples were drawn using a heparinized syringe from the jugular or ear vein at 0.25, 0.5, 1, 2, 3, 5, 8, and 24 h after administration. Blood was centrifuged at 3000 rpm for 10 min at room temperature. The concentrations of 1i and Pactimibe in the plasma were determined using HPLC. In another set of experiments, 1i (30 mg/kg) and Pactimibe (10 mg/kg) were orally administered, blood was taken, and the atherosclerotic aorta was isolated after euthanasia by deep anesthesia. The concentrations of both compounds in the plasma and aorta were determined using HPLC, and the partition ratio from plasma to the aorta was calculated.
Esterified Cholesterol (EC) Accumulation in THP-1 Cell-Derived Macrophages: The effects of the test compounds on EC accumulation in THP-1 cells were determined during differentiation and foam cell formation. In order to cause the cells to differentiate into macrophages and to form foam cells, THP-1 cells were suspended in RPMI-1640 medium containing fetal bovine serum (FBS, 10%) and phorbol 12-myristate 13-acetate (PMA, 200 nM) with acetyl low density lipoprotein (LDL) (400 mg protein/ml), and then they were incubated at 4ϫ10 5 cells/well in a humidified atmosphere of 95% air, 5% CO 2 at 37°C for 3 d in the presence or absence of the test compounds. Acetyl LDL was prepared from the serum of male KHC rabbits (6-8 months old; Japan Laboratory Animals, Inc., Tokyo, Japan). In another set of experiments, the effects of compound 1i and Pactimibe on EC accumulation by high-cholesterol serum (HCS) were investigated in the presence of bovine serum albumin (BSA). THP-1 cells were suspended in RPMI-1640 medium containing FBS (10%) and PMA (200 nM), incubated at 4ϫ10 5 cells/well in a humidified atmosphere of 95% air, 5% CO 2 at 37°C for 3 d, and then they were incubated in RPMI-1640 medium containing HCS (3%) with or without BSA (5%) in the presence or absence of the test compounds for a day. HCS was isolated from male JW rabbits (4-5 months old; Japan SLC Inc.) fed a high cholesterol diet for 1 month. Cellular cholesterol was extracted by n-hexane/i-PrOH (3 : 2) and determined by enzymatic methods. EC content was calculated by subtracting the amount of free cholesterol from the total amount of cholesterol. Cellular protein was measured by Lowry's method.
In Vitro ACAT Activity: Male JW rabbits (2.5 kg, Japan SLC) were anesthetized with sodium pentobarbital (30 mg/kg, intravenously (i.v.)) and exsanguinated from the common carotid artery, and then the liver was isolated. Microsomes were prepared according to the method of Field and Mathur. 17) Briefly, each sample was homogenized in a buffered sucrose solution (250 mM sucrose, 5 mM K 2 HPO 4 /KH 2 PO 4 , 1 mM ethylenediaminetetraacetic acid (EDTA), and 1 mM dithioerythritol, pH 7.4) using a Teflon-glass homogenizer. The homogenate was centrifuged at 12000ϫg for 15 min at 4°C. The resulting supernatant was centrifuged at 105000ϫg for 30 min at 4°C. The microsomal fraction was used as the ACAT preparation. ACAT activity was determined according to the method described by Heider et al. 18) The microsomes were incubated in 154 mM phosphate buffer (pH 7.4) containing bovine serum albumin. Test compounds were applied and preincubated at 37°C for 5 min, and then 30 nmol of [1- 14 C]oleoyl-CoA (PerkinElmer, Waltham, MA, U.S.A.) was added. The reaction mixture was incubated at 37°C for 20 min. Lipids were extracted with CHCl 3 /MeOH (2 : 1) and separated by thin-layer chromatography. The EC produced in microsomes treated with vehicle and test compounds were determined. IC 50 values were calculated using data at the concentrations of test compounds in each experiment and the mean value was calculated for 2 experiments.
In Vitro Cholesterol Esterification in Atherosclerotic Aorta The aorta was isolated from KHC rabbits, and atherosclerotic areas were minced and then equally weighed out 200 mg samples. These aortic samples were treated with compounds 1i and Pactimibe and incubated with 14 C-oleic acid at 37°C for 24 h in JW rabbit serum. Then, lipids were extracted with CHCl 3 /MeOH (2 : 1) and separated by TLC. The EC produced in the samples incubated with vehicle or test compounds was determined.
